ArticleNanomedicine (London, England)2025
An uphill path to commercialization of silver nanoparticle antimicrobials: from bench to market.
Sanil Nadar et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
4 papers cite it
this papercites it